Cytosorbents (CTSO) CEO Phillip Chan Buys Stock

What Happened Phillip P. Chan, Chief Executive Officer of Cytosorbents Corporation (CTSO), made an open-market purchase of 3,774 shares on September 15, 2026 at $6.00 per share, for a total cash outlay of $22,644. The Form 4 reports this as a purchase (transaction code P) and footnote F1 confirms it was an open market buy.

Key Details

• Transaction date and price: 2026-09-15 — 3,774 shares at $6.00 each (total $22,644).
• Ownership after transaction: the filing lists 83,782 shares of Common Stock owned plus the 3,774 shares purchased, for a combined 87,556 shares beneficially owned (in addition to RSUs described below).
• RSUs and contingent holdings (per footnotes): 10,800 RSUs that vest on a Change in Control (grants from 2015–2018) and 2,640 RSUs (part of a 5,280 grant from 2025) that vest over two years — total 13,440 RSUs currently outstanding.
• Reverse split: all share figures reflect a 1-for-20 reverse stock split effective September 8, 2026 (footnote F4).
• Filing timeliness: The Form 4 was filed on 2026-09-16 for the 2026-09-15 transaction (no late-filing flag shown).
• Footnotes: F1 confirms open-market purchase; F2–F3 detail RSUs and existing share ownership.

Context This was a straightforward open-market purchase (not an option exercise, gift, or withholding-related transaction). The dollar amount is modest ($22.6k) relative to large insider trades, but purchases are often watched by investors as one data point about insider sentiment. The filing also discloses significant contingent RSUs that vest on a change in control and time-based RSUs that may convert to shares in the future.